Published Paper Details:

Granisetron is a potent and selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist widely used for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). Despite its therapeutic efficacy, granisetron exhibits a relatively short biological half-life and requires frequent administration, which may reduce patient compliance. Gastroretentive drug delivery systems (GRDDS), particularly floating drug delivery systems (FDDS), have gained significant attention as an approach to enhance gastric residence time and improve drug bioavailability. FDDS are designed to remain buoyant in gastric fluid, thereby prolonging drug release in the upper gastrointestinal tract where absorption is optimal. This review provides a detailed overview of granisetron, including its pharmacokinetics and limitations, and discusses the design principles, formulation strategies, mechanisms, and evaluation parameters of floating drug delivery systems. Various polymers, excipients, and preparation techniques used in FDDS are critically examined. Additionally, recent advancements and future perspectives in gastroretentive systems for granisetron delivery are highlighted. The review concludes that FDDS represent a promising strategy for improving therapeutic outcomes and patient adherence in granisetron therapy.